GlassScriptPhysician profile
Rahul Solanki
NPI 1225245509
$1,206.53
in general payments reported to CMS, 2019-2025
13 companies · $64.99 in 2025
The $64.99 reported for 2025 was less than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.37 · 2022: $207 · 2023: $451 · 2024: $465 · 2025: $64.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.28 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $375.86 | 2023-2025 | Wakix |
| Inspire Medical Systems, INC. | $275.47 | 2023-2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $132.81 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $103.83 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $54.36 | 2022 | |
| Astellas Pharma US INC | $49.23 | 2022 | |
| Abbvie INC. | $43.19 | 2022 | |
| Lilly USA, LLC | $38.95 | 2022 | |
| Glaxosmithkline, LLC. | $34.12 | 2020-2023 | Trelegy Ellipta |
| United Therapeutics Corporation | $31.57 | 2024 | Tyvaso, Remodulin, Orenitram |
| Philips North America LLC | $26.81 | 2023-2024 | (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $21.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.16 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Solanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.